Investigation of patients with abnormal response to warfarin
- PMID: 3741725
- PMCID: PMC1401092
- DOI: 10.1111/j.1365-2125.1986.tb02877.x
Investigation of patients with abnormal response to warfarin
Abstract
In 55 patients in whom warfarin control had been satisfactory for at least 4 months, warfarin dose, plasma warfarin concentration and plasma clearance were measured. The mean dose to maintain the BCR (INR) between 2.3 and 3.3 was 5.1 +/- 2 mg day-1 (range 1.5-10 mg). Plasma warfarin concentrations and warfarin clearance were log-normally distributed with 95% confidence limits between 0.8 and 2.4 mg l-1 and 2.5 and 8.71 day-1 respectively. These confidence limits were used to construct algorithms which correctly predicted the cause of abnormal warfarin sensitivity in two patients and resistance in two further patients. These algorithms should help to identify the cause of abnormal warfarin responsiveness in the clinical setting.
Similar articles
-
Interaction of sulphinpyrazone with warfarin.Eur J Clin Pharmacol. 1982;22(4):327-31. doi: 10.1007/BF00548401. Eur J Clin Pharmacol. 1982. PMID: 7106169
-
Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects.Br J Clin Pharmacol. 2015 Jun;79(6):907-17. doi: 10.1111/bcp.12559. Br J Clin Pharmacol. 2015. PMID: 25475601 Free PMC article. Clinical Trial.
-
Role of desethylamiodarone in the anticoagulant effect of concurrent amiodarone and warfarin therapy.J Cardiovasc Pharmacol Ther. 2001 Oct;6(4):363-7. doi: 10.1177/107424840100600405. J Cardiovasc Pharmacol Ther. 2001. PMID: 11907638 Clinical Trial.
-
A flexible loading dose schedule for warfarin therapy.Scott Med J. 1987 Dec;32(6):169-71. doi: 10.1177/003693308703200604. Scott Med J. 1987. PMID: 3329767 Clinical Trial.
-
Warfarin therapy: evolving strategies in anticoagulation.Am Fam Physician. 1999 Feb 1;59(3):635-46. Am Fam Physician. 1999. PMID: 10029789 Review.
Cited by
-
Case studies in therapeutics: warfarin resistance and inefficacy in a man with recurrent thromboembolism, and anticoagulant-associated priapism.Br J Clin Pharmacol. 1998 Oct;46(4):343-6. doi: 10.1046/j.1365-2125.1998.t01-1-00796.x. Br J Clin Pharmacol. 1998. PMID: 9803981 Free PMC article.
-
Anticoagulant therapy in special circumstances.Curr Cardiol Rep. 2000 Jan;2(1):74-9. doi: 10.1007/s11886-000-0029-y. Curr Cardiol Rep. 2000. PMID: 10980876 Review.
-
Clinical utilization of the international normalized ratio (INR).J Clin Lab Anal. 2000;14(3):101-14. doi: 10.1002/(sici)1098-2825(2000)14:3<101::aid-jcla4>3.0.co;2-a. J Clin Lab Anal. 2000. PMID: 10797608 Free PMC article. Review.
-
Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy.Br J Clin Pharmacol. 1999 Jul;48(1):63-70. doi: 10.1046/j.1365-2125.1999.00967.x. Br J Clin Pharmacol. 1999. PMID: 10383562 Free PMC article.
-
The Smith Kline & French lecture 1987. Clinical pharmacology and the art of bespoke prescribing.Br J Clin Pharmacol. 1988 Oct;26(4):339-45. doi: 10.1111/j.1365-2125.1988.tb03390.x. Br J Clin Pharmacol. 1988. PMID: 3056481 Free PMC article. Review. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical